PRLX-93936
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 202334

CAS#: 903499-49-0

Description: PRLX 93936 is a structural analogue of erastin with potential antineoplastic activity. Erastin analogue PRLX 93936 appears to inhibit mitochondrial outer membrane protein VDACs (voltage-dependent anion channels) 2 and 3, resulting in an oxidative, non-apoptotic cell death. Erastin analogue PRLX 93936 exhibits greater lethality in cell lines harboring mutations in the GTPase protein oncogenes HRAS and KRAS or the serine-threonine protein kinase oncogene BRAF than in non-tumorigenic cell lines. VDACs 2 and 3 are up-regulated in a wide variety of tumor cell lines.

Chemical Structure

img
PRLX-93936
CAS# 903499-49-0
Handing Instruction

Theoretical Analysis

MedKoo Cat#: 202334
Name: PRLX-93936
CAS#: 903499-49-0
Chemical Formula: C21H24N4O2
Exact Mass: 364.1899
Molecular Weight: 364.449
Elemental Analysis: C, 69.21; H, 6.64; N, 15.37; O, 8.78

Size Price Shipping out time Quantity
5mg USD 370 2 Weeks
10mg USD 630 2 Weeks
25mg USD 1180 2 Weeks
Inquire bulk and customized quantity
Pricing updated 2021-03-01. Prices are subject to change without notice.

PRLX93936, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Synonym: PRLX93936; PRLX 93936; PRLX-93936; analogue of erastin.

IUPAC/Chemical Name: 3-(2-ethoxyphenyl)-2-(piperazin-1-ylmethyl)quinazolin-4(3H)-one

InChi Key: OBWOSMGNXYUDFB-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H24N4O2/c1-2-27-19-10-6-5-9-18(19)25-20(15-24-13-11-22-12-14-24)23-17-8-4-3-7-16(17)21(25)26/h3-10,22H,2,11-15H2,1H3

SMILES Code: O=C1N(C2=CC=CC=C2OCC)C(CN3CCNCC3)=NC4=C1C=CC=C4

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not soluble in water.

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Certificate of Analysis:
View CoA: current batch, Lot#C8M12C19

Safety Data Sheet (SDS):
View Safety Data Sheet (SDS)

Handling Instructions:
View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 364.449 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

img

PRLX-93936

5mg / USD 370


Additional Information

PRLX 93936 is a product of extensive SAR work originating from a small molecule identified in a synthetic lethal screen against isogenic cell lines engineered to differentially express several genes including activated RasV12. Preclinical pharmacodynamic and toxicological studies, suggest that PRLX 93936 has great therapeutic potential and therefore, Prolexys initiated a Phase I clinical trial in August, 2007.

Note: Structure was from http://www.chemspider.com/Chemical-Structure.9734401.html (5/31/2016).